RNS Number: 68020 Phoenix Group Holdings PLC 04 December 2024

LEI: 2138001P49OLAEU33T68

4 December 2024

Phoenix Group Holdings plc - Board Changes

The Board of Phoenix Group Holdings plc ("Phoenix" or the "Group") is pleased to announce that Mark Gregory will succeed John Pollock as Chair of the Risk Committee with effect from 4 December 2024 subject to regulatory approval.

Mark joined the Board as an Independent Non-Executive Director on 1 April 2023 and has served as a member of the Risk Committee since that date.

John Pollock will retire as Chair of the Risk Committee with effect from 3 December 2024 and from the Board on 31 December 2024 having served almost eight and a half years.

Commenting on the change, Sir Nick Lyons, Chair of Phoenix said:

"I would like to thank John for the significant contribution he has made to the Group during his time on the Board, in particular as Chair of the Risk Committee for the past 8 years. Mark is an experienced Risk Committee Chair as he is also Chair of the Risk Committee at Direct Line Insurance Group plc."

This announcement is made pursuant to LR 6.4.6 of the Listing Rules.

Enquiries:

Media

Shellie Wells, Corporate Communications Director,

Phoenix Group

+44 (0) 204 559 3031

Tom Murray

Senior Managing Director, Teneo

+44 (0) 7813 166798

Investors

Claire Hawkins, Director of Corporate Affairs

& Brand, Phoenix Group

+44 (0) 204 559 3161

Joanne Roberts, Investor Relations Director,

Phoenix Group

+44 (0) 204 559 4673

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact <a href="mailto:msc.ukm.nc.ukm.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our <u>Privacy Policy</u>.

END

BOAZZMGZRFZGDZM